Overview reveals safety and efficacy enhancements of the Respimat inhaler for COPD management, indicating improved drug delivery.
Introduction The Respimat Soft Mist Inhaler (SMI), introduced in the early 2000s, represented a significant, represented a significant advancement in inhaled drug delivery for chronic obstructive pulmonary disease (COPD). It offers improved lung deposition, lower oropharyngeal impaction, and enhanced ease of use compared to traditional pressurized or dry powder inhalers.
No takes yet. Share an insight, caveat, or question.
Sorano et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: